OraSure Technologies, Inc. (OSUR)Healthcare | Medical Instruments & Supplies | Bethlehem, United States | NasdaqGS
3.60 USD
-0.09
(-2.439%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.60 |
Hot Take ↕ | Aug. 22, 2026, 2:24 a.m. EDT
The investment case for OraSure is fundamentally broken. The company is generating negative free cash flow and posting losses, with a forward P/E that is mathematically undefined due to negative earnings. While the balance sheet shows a high current ratio, this liquidity is being consumed by operational losses rather than funding growth, evidenced by the 1% revenue contraction and a 57% cumulative decline over the last nine years. The stock has suffered two consecutive years of negative returns, confirming a structural deterioration in business quality. There is no dividend to provide income, and the recent price action shows weakness relative to the 200-day average. Although the options market sees a wall of call interest at $5, this appears to be speculative hope rather than a genuine belief in a turnaround, given the absence of any put buying to hedge against the inevitable further downside. The consensus 'Hold' rating reflects the reality that there is no clear path to recovery without significant operational restructuring, which is not currently visible in the data. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.053148 |
| MSTL | 0.053711 |
| AutoETS | 0.056755 |
| AutoTheta | 0.060484 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 0.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.464 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 1998-01-07 |
| Debt to Equity Ratio | 3.806 |
| Revenue per Share | 1.588 |
| Market Cap | 248,287,040 |
| Forward P/E | -5.45 |
| Beta | 1.01 |
| Profit Margins | -43.70% |
| Website | https://www.orasure.com |
As of Aug. 22, 2026, 2:24 a.m. EDT: Call buyers are heavily concentrated at the $5.00 strike, creating a significant barrier for upside movement, while put volume is negligible. This asymmetry suggests speculators are positioning for a range-bound scenario or a slow grind higher rather than a sharp crash, though the lack of put protection indicates limited hedging against downside risk.
| Date | Dividend | Yield % |
|---|---|---|
| 1998-01-08 | 1.6 | 30.843373 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.07142854 |
| Address1 | 220 East First Street |
| All Time High | 27.5 |
| All Time Low | 1.791667 |
| Ask | 3.6 |
| Ask Size | 3 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 403,180 |
| Average Daily Volume3 Month | 529,055 |
| Average Volume | 529,055 |
| Average Volume10Days | 403,180 |
| Beta | 1.008 |
| Bid | 2.66 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 4.608 |
| City | Bethlehem |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 1 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.6 |
| Current Ratio | 8.875 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.73 |
| Day Low | 3.58 |
| Debt To Equity | 3.806 |
| Display Name | OraSure |
| Earnings Call Timestamp End | 1,785,963,600 |
| Earnings Call Timestamp Start | 1,785,963,600 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -61,556,000 |
| Ebitda Margins | -0.54759 |
| Enterprise To Ebitda | -1.621 |
| Enterprise To Revenue | 0.888 |
| Enterprise Value | 99,799,056 |
| Eps Current Year | -0.8 |
| Eps Forward | -0.66 |
| Eps Trailing Twelve Months | -0.67 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0514 |
| Fifty Day Average Change | -0.45140028 |
| Fifty Day Average Change Percent | -0.11141834 |
| Fifty Two Week Change Percent | 7.1428537 |
| Fifty Two Week High | 4.58 |
| Fifty Two Week High Change | -0.98 |
| Fifty Two Week High Change Percent | -0.2139738 |
| Fifty Two Week Low | 2.08 |
| Fifty Two Week Low Change | 1.52 |
| Fifty Two Week Low Change Percent | 0.7307693 |
| Fifty Two Week Range | 2.08 - 4.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 532,621,800,000 |
| Float Shares | 60,861,365 |
| Forward Eps | -0.66 |
| Forward P E | -5.454545 |
| Free Cashflow | -44,569,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 500 |
| Fullday Change | -0.0900002 |
| Fullday Change Percent | -2.43903 |
| Fullday Price | 3.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.42633998 |
| Gross Profits | 47,926,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06371 |
| Held Percent Institutions | 0.82727 |
| Implied Shares Outstanding | 68,968,627 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=99740&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 884,217,600 |
| Last Dividend Value | 1.6 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 544,838,400 |
| Last Split Factor | 3:1 |
| Long Business Summary | OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania. |
| Long Name | OraSure Technologies, Inc. |
| Market | us_market |
| Market Cap | 248,287,040 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_540470 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -49,126,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 254,839,076 |
| Number Of Analyst Opinions | 1 |
| Open | 3.7 |
| Operating Cashflow | -42,883,000 |
| Operating Margins | -0.55984 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 6.19 |
| Phone | 610 882 1820 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.6 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 3.69 |
| Price Eps Current Year | -4.5 |
| Price Hint | 4 |
| Price To Book | 0.78125 |
| Price To Sales Trailing12 Months | 2.2087235 |
| Profit Margins | -0.43702 |
| Quick Ratio | 7.482 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0900002 |
| Regular Market Change Percent | -2.43903 |
| Regular Market Day High | 3.73 |
| Regular Market Day Low | 3.58 |
| Regular Market Day Range | 3.58 - 3.73 |
| Regular Market Open | 3.7 |
| Regular Market Previous Close | 3.69 |
| Regular Market Price | 3.6 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 249,957 |
| Return On Assets | -0.110360004 |
| Return On Equity | -0.14066 |
| Revenue Growth | -0.019 |
| Revenue Per Share | 1.588 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 68,968,627 |
| Shares Percent Shares Out | 0.0456 |
| Shares Short | 3,143,610 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,265,238 |
| Short Name | OraSure Technologies, Inc. |
| Short Percent Of Float | 0.0479 |
| Short Ratio | 7.25 |
| Source Interval | 15 |
| State | PA |
| Symbol | OSUR |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 160,582,000 |
| Total Cash Per Share | 2.328 |
| Total Debt | 12,094,000 |
| Total Revenue | 112,412,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.22525 |
| Two Hundred Day Average Change | 0.3747499 |
| Two Hundred Day Average Change Percent | 0.11619251 |
| Type Disp | Equity |
| Volume | 249,957 |
| Website | https://www.orasure.com |
| Zip | 18,015 |